Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v15-FR | Version v8-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2025-11-17 | 2025-09-18 |
| Drug Identification Number | 02236926 | 02236926 |
| Brand name | ACYCLOVIR SODIUM INJECTION | ACYCLOVIR SODIUM INJECTION |
| Common or Proper name | Acyclovir Sodium Injection 50mg/mL, 20 mL vial | Acyclovir Sodium Injection 50mg/mL, 20 mL vial |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | ACYCLOVIR | ACYCLOVIR |
| Strength(s) | 50MG | 50MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 20 mL | 20 mL |
| ATC code | J05AB | J05AB |
| ATC description | DIRECT ACTING ANTIVIRALS | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2025-09-18 | 2025-09-18 |
| Estimated end date | 2026-02-09 | 2025-12-19 |
| Actual end date | ||
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due an increase in demand from a market shortage, we will be encountering a supply interruption on our Acyclovir Sodium Injection 50 mg/mL, 20 mL Vial effective September 18, 2025, until December 19, 2025 | Fresenius Kabi Canada regrets to advise that, due to a decommission of the manufacturing line this product will be transferred to another manufacturing facility, and we will be encountering a supply interrumption. |
| Health Canada comments |